ライブラリ登録: Guest
Critical Reviews™ in Neurobiology

年間 3 号発行

ISSN 印刷: 0892-0915

ISSN オンライン: 2375-0014

SJR: 0.121

AMPA Receptor Blockade Potentiates the Stimulatory Effect of L-DOPA on Dopamine Release in Dopamine-Deficient Corticostriatal Slice Preparation

巻 16, 発行 1&2, 2004, pp. 129-139
DOI: 10.1615/CritRevNeurobiol.v16.i12.140
Get accessGet access

要約

The release of [3H]dopamine was measured in rat corticostriatal slice preparations that contained the striatum and the adjacent prefrontal cortex to maintained glutamatergic corticostriatal afferentation. These slices were prepared from either nontreated or 6-hydroxydopamine—pretreated rats. The slices were loaded with [3H]dopamine, submerged in a two-compartment bath so that the cortical region was contained in one compartment, the corpus callosum was passed through a silicone greased slot, and the striatal region was contained in the other compartment. The cortical and the striatal parts were superfused with Krebs-bicarbonate buffer independently. The release of [3H]dopamine was determined from the striatal part at rest and in response to electrical stimulation of the cortical area. Electrical stimulation of the cortical part increased the release of [3H]dopamine from the striatal part of the slices, and this release was found to be higher after lesion of the nigrostriatal dopaminergic pathway with 6-hydroxydopamine. Cortically evoked [3H]dopamine release was even higher in the presence of the dopamine precursor L-DOPA after 6-hydroxdopamine lesion. Perfusion of GYKI-53405, a noncompetitive AMPA receptor antagonist, in combination with L-DOPA further increased both basal and stimulation-evoked [3H]dopamine release, whereas GYKI-53405 by itself did not influence basal [3H]dopamine outflow from striatum. These findings indicate that, in parkinsonian striatum, the stimulatory effect of L-DOPA on dopamine release is potentiated by AMPA receptor blockade, and the antiparkinsonian effect of GYKI-53405 may be due to its L-DOPA sparing effect.

によって引用された
  1. Gigler G, Móricz K, ágoston M, Simó A, Albert M, Benedek A, Kapus G, Kertész S, Vegh M, Barkóczy J, Markó B, Szabó G, Matucz É, Gacsályi I, Lévay G, Hársing L G, Szénási G, Neuroprotective and anticonvulsant effects of EGIS-8332, a non-competitive AMPA receptor antagonist, in a range of animal models, British Journal of Pharmacology, 152, 1, 2007. Crossref

  2. Müller Thomas, Russ Hermann, Levodopa, motor fluctuations and dyskinesia in Parkinson’s disease, Expert Opinion on Pharmacotherapy, 7, 13, 2006. Crossref

  3. Bibbiani F., Oh J.D., Kielaite A., Collins M.A., Smith C., Chase T.N., Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD, Experimental Neurology, 196, 2, 2005. Crossref

  4. Szénási Gábor, Vegh Miklos, Szabo Geza, Kertesz Szabolcs, Kapus Gabor, Albert Mihaly, Greff Zoltan, Ling Istvan, Barkoczy Jozsef, Simig Gyula, Spedding Michael, Harsing Laszlo G., 2,3-Benzodiazepine-type AMPA receptor antagonists and their neuroprotective effects, Neurochemistry International, 52, 1-2, 2008. Crossref

  5. Milusheva Elisaveta, Baranyi Mária, Kormos Eszter, Hracskó Zsuzsanna, Sylvester Vizi E., Sperlágh Beáta, The effect of antiparkinsonian drugs on oxidative stress induced pathological [3H]dopamine efflux after in vitro rotenone exposure in rat striatal slices, Neuropharmacology, 58, 4-5, 2010. Crossref

  6. Megyeri Katalin, Marko Bernadett, Sziray Nora, Gacsalyi Istvan, Juranyi Zsolt, Levay Gyorgy, Harsing Laszlo G., Effects of 2,3-benzodiazepine AMPA receptor antagonists on dopamine turnover in the striatum of rats with experimental parkinsonism, Brain Research Bulletin, 71, 5, 2007. Crossref

  7. Maranis Sotirios, Stamatis Dimitrios, Tsironis Christos, Konitsiotis Spiridon, Investigation of the antidyskinetic site of action of metabotropic and ionotropic glutamate receptor antagonists. Intracerebral infusions in 6-hydroxydopamine-lesioned rats with levodopa-induced dyskinesia, European Journal of Pharmacology, 683, 1-3, 2012. Crossref

  8. Gasparini Fabrizio, Di Paolo Thérèse, Gomez-Mancilla Baltazar, Metabotropic Glutamate Receptors for Parkinson's Disease Therapy, Parkinson's Disease, 2013, 2013. Crossref

  9. Bastide Matthieu F., Meissner Wassilios G., Picconi Barbara, Fasano Stefania, Fernagut Pierre-Olivier, Feyder Michael, Francardo Veronica, Alcacer Cristina, Ding Yunmin, Brambilla Riccardo, Fisone Gilberto, Jon Stoessl A., Bourdenx Mathieu, Engeln Michel, Navailles Sylvia, De Deurwaerdère Philippe, Ko Wai Kin D., Simola Nicola, Morelli Micaela, Groc Laurent, Rodriguez Maria-Cruz, Gurevich Eugenia V., Quik Maryka, Morari Michele, Mellone Manuela, Gardoni Fabrizio, Tronci Elisabetta, Guehl Dominique, Tison François, Crossman Alan R., Kang Un Jung, Steece-Collier Kathy, Fox Susan, Carta Manolo, Angela Cenci M., Bézard Erwan, Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease, Progress in Neurobiology, 132, 2015. Crossref

  10. Harsing L. G., Dopamine and the Dopaminergic Systems of the Brain, in Handbook of Neurochemistry and Molecular Neurobiology, 2008. Crossref

Begell Digital Portal Begellデジタルライブラリー 電子書籍 ジャーナル 参考文献と会報 リサーチ集 価格及び購読のポリシー Begell House 連絡先 Language English 中文 Русский Português German French Spain